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Abstract
Ultrasound-targeted microbubble destruction (UTMD) is a
novel means of tissue-specific gene delivery. This approach
systemically infuses transgenes precoupled to gas-filled lipid
microbubbles that are burst within the microvasculature of tar-
get tissues via an ultrasound signal resulting in release of
DNA and transfection of neighboring cells within the tissue.
Previous work has shown that adenovirus containing cDNA of
UCP-1, injected into the epididymal fat pads in mice, induced
localized fat depletion, improving glucose tolerance, and
decreasing food intake in obese diabetic mice. Our group
recently demonstrated that gene therapy by UTMD achieved
beta cell regeneration in streptozotocin (STZ)-treated mice and
baboons. We hypothesized that gene therapy with BMP7/
PRDM16/PPARGC1A in skeletal muscle (SKM) of obese Zucker
diabetic fatty (fa/fa) rats using UTMD technology would pro-
duce a brown adipose tissue (BAT) phenotype with UCP-1
overexpression. This study was designed as a proof of con-
cept (POC) project. Obese Zucker rats were administered
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plasmid cDNA contructs encoding a gene cocktail with BMP7/
PRDM16/PPARGC1A incorporated within microbubbles and
intravenously delivered into their left thigh. Controls received
UTMD with plasmids driving a DsRed reporter gene. An ultra-
sound transducer was directed to the thigh to disrupt the
microbubbles within the microcirculation. Blood samples were
drawn at baseline, and after treatment to measure glucose,
insulin, and free fatty acids levels. SKM was harvested for
immunohistochemistry (IHC). Our IHC results showed a reli-
able pattern of effective UTMD-based gene delivery in
enhancing SKM overexpression of the UCP-1 gene. This
clearly indicates that our plasmid DNA construct encoding the
gene combination of PRDM16, PPARGC1A, and BMP7 reprog-
rammed adult SKM tissue into brown adipose cells in vivo.
Our pilot established POC showing that the administration of
the gene cocktail to SKM in this rat model of genetic obesity
using UTMD gene therapy, engineered a BAT phenotype with
UCP-1 over-expression. VC 2017 IUBMB Life, 69(9):745–755,
2017
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UCP-1
Introduction
The genetic basis of obesity is a process regulated by changes
in expression of specific proteins; therefore, genetic defects
within the corresponding coding or regulatory DNA sequences
constitute its cellular and genomic foundations (1). New strate-
gies for weight loss treatment and prevention of obesity-
related comorbidities are urgently needed to successfully
reverse or prevent the health complications caused by fat
accumulation (2,3). Uncoupling protein-1 (UCP-1) is exclusively
found in brown adipose tissue (BAT). Similar to skeletal mus-
cle (SKM), BAT contains a much higher number of mitochon-
dria compared with white adipose tissue (WAT) (4) and a spe-
cialized, specific UCP-1. This specialized protein uncouples
ATP production from mitochondrial respiration and converts
energy into heat. The manipulation of BAT is a promising and
significant strategy in combating obesity, since it contributes to
the regulation of whole-body energy expenditure (EE) and
body fat content (5). Gene therapy is designed to transfer
genetic material with the intent of providing therapeutic poten-
tial. Gene therapy commonly uses viral vectors as a viable
solution for gene therapy delivery systems (6). However, bio-
safety concerns greatly limited viral vector application. In con-
trast, non-viral gene therapy offers gene delivery without
potential complications of toxicity, altered immune response,
and decreased capability to target specific cells (7,8). The
focus of obesity-related gene therapy is to favor EE and lipoly-
sis by modulating expression of appropriate gene targets to
restore and maintain energy homeostasis. Exciting work in
rodents has shown that adenovirus containing the cDNA of
UCP-1 induced localized fat depletion, improved glucose toler-
ance, and decreased food intake when injected into the epidid-
ymal fat pads of obese and diabetic mice. This increased fat
combustion resulted from an increased expression of UCP-1 in
WAT. Generating new BAT via gene therapy is a promising
approach (9,10).
Ultrasound-targeted microbubble destruction (UTMD)
technology is a non-viral, novel approach to gene therapy in
which plasmid DNA is targeted to specific tissues and organs
in vivo (11). The UTMD technique has successfully driven
expression of plasmid cDNA in rat (12) and baboon pancreatic
islets, encoding pancreatic genes known to be involved in islet
development (13). Our research group is the first to apply
UTMD to the study of metabolic disorders in nonhuman pri-
mates (13). The delivery of genes by intravenously injecting
plasmid DNA encapsulated in microbubbles into the animal’s
blood stream, to lyse them selectively in the microcirculation
of specific organs via ultrasound, is highly innovative (14).
This proof of concept (POC) project was designed to deter-
mine whether the administration of a gene cocktail with
BMP7/PRDM16/PPARGC1A in SKM of Zucker diabetic fatty
(ZDF) (fa/fa) rats using UTMD technology will produce a BAT
phenotype with UCP-1 overexpression. This research proposal
was based on recent findings which indicate that WAT and
BAT have distinct developmental origins (15). A common line-
age for SKM and BAT has been proposed different to WAT.
Unlike white adipose cells that originate from Myf5 negative (–
) precursors and are derived from blood vessel-associated
pericyte-like cells, SKM and BAT are derived from precursors
expressing the key myogenic factor Myf5 positive (1) (16). Adi-
pogenesis is controlled by bone morphogenetic proteins
(BMPs). BMP2 and 4 promote the development of WAT,
whereas BMP7 promotes the development of BAT (17). BMP7
also induces the expression of PRDM16 which functions to pro-
mote BAT gene expression and suppress the white fat program
(18). The cascade of events is triggered as follows: precursor
cells, positive for the muscle developmental gene Myf5, are
stimulated by BMP7 to express PRDM16 which acts as a switch
to instigate the brown fat differentiation pathway and inhibit
the WAT and myogenic pathway. PRDM16 acts to induce the
expression of PPARGC1A. Activation of PPARGC1A by BMP7
and PRDM16 drives a complete brown fat differentiation pro-
gram and UCP-1 expression, the hallmark of BAT (19).
In this POC pilot study, we showed that by administering
tissue-specific UTMD gene therapy, we were able to obtain
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overexpression of UCP-1 in the SKM of ZDF fa/fa rats. Two
rats received UTMD with plasmids driving BMP7/PRDM16/
PPARGC1A genes, and two controls received UTMD with plas-
mids driving the DsRed reporter gene. We examined the cellu-
lar consequences of UTMD delivery of BMP7/PRDM16/
PPARGC1A genes into SKM and showed that the gene cocktail
converted this tissue into a brown fat phenotype, causing
molecular changes to transform it into brown adipose-like,
mitochondrial UCP1-abundant cells able to increase fat and
glucose oxidation.
Materials and Methods
Experimental Animals
Obese ZDF (fa/fa) male rats were purchased from Charles
River Laboratories, housed in a temperature-controlled envi-
ronment under a 12:12-h light–dark cycle and were fed ad
libitum. Animal facilities met the guidelines of the National
Institutes of Health recommendations and the approval of our
institutional animal research committee. Animals received reg-
ular chow for the length of the study. A total of four rats
received: (1) UTMD with pCMV-DsRed plasmid (n52); (2)
UTMD with a gene cocktail with PRDM16, PPARGC1A, and
BMP7 (n52). All genes were delivered as plasmid cDNA.
PRDM16 (pcDNA3.1, Catalog no. 15503, deposited by Bruce
Spiegelman Lab.) and PPARGC1A (pcDNA4myc, Catalog no.
10974, deposited by Toren Finkel Lab.) were obtained from
the nonprofit plasmid repository Addgene. BMP7 (untagged-
human BMP7) Catalog no. sc119058) was purchased from Ori-
Gene Technologies. Weight measurement was performed in
the rats with an Ohaus-Valor 3000 XTREME scale. The thick-
ness of subcutaneous (SQ) adipose tissue was determined by
ultrasound image. Food intake was measured on a daily basis.
Manufacture of Plasmid-Containing Lipid-Stabilized
Microbubbles
Lipid-stabilized microbubbles were prepared as described pre-
viously (13). Briefly, a stock solution is prepared containing
270 mg of 1,2-dipalmitoyl-Sn-glycero-3-phosphatidylcholine,
(Sigma, St. Louis, MO), 30 mg of 1,2-dipalmitoyl-Sn-glycero-3-
phosphatidylethanolamine, (Sigma, St. Louis, MO), and 1 g of
glucose. These ingredients are dissolved in a boiling water
bath for 20–30 min, with pipetting of contents up and down
until no visible particles remain. This stock solution is stored
at 4 8C. Plasmid containing microbubbles are prepared by mix-
ing 2 mg of dried plasmid with 50 lL of lipofectamine 2000
(Invitrogen, Carlsbad, CA) and incubating at room temperature
for 15 min. This liposome/plasmid DNA mixture is added to
250 mL of lipid stock solution, 50 mL of pure glycerol, and 5
lL of 10% albumin solution, mixed well with a pipette, and
then placed in ice. Aliquots of 0.5 mL of this phospholipid–
plasmid solution are placed in 1.5 mL clear vials; the air in the
headspace of the vials is replaced with perfluoropropane gas
(Air Products, Inc, Allentown, PA). Each vial is incubated at
4 8C for 30 min and then mechanically shaken for 30 sec by a
dental amalgamator (VialmixTM, Bristol-Myers Squibb Medical
Imaging, N. Billerica, MA). The lipid-stabilized microbubbles
appear as a milky white suspension floating on the top of a
layer of liquid containing unattached plasmid DNA. The subna-
tant is discarded and the microbubbles were washed three
times with phosphate-buffered solution (PBS) to remove unat-
tached plasmid DNA. The mean diameter and concentration of
the microbubbles in the upper layer are measured by a parti-
cle counter (Beckman Coulter Multisizer III).
Delivery of Plasmid cDNA Contructs Encoding the
Gene Cocktail with BMP7/PRDM16/PPARGC1A into the
Left Thigh of the Rats
The microbubbles were infused intravenously under anesthe-
sia. The microbubble suspension (driving the gene cocktail
with BMP7/PRDM16/PPARGC1A) or control solutions (0.5 mL
diluted with 0.5 mL PBS) were infused over 5 min via pump
(Genie, Kent Scientific). Plasmid DNA containing the reporter
gene DsRed or the functional gene cocktail construct under the
regulation of a cytomegalovirus promoter was incorporated
within the phospholipid shell of perfluoropropane gas-filled
microbubbles. These plasmid constructs with routine plasmid
vectors were isolated with cloning techniques and gene pro-
moter construction. The plasmid-containing lipid-stabilized
microbubbles were prepared following procedures described
previously (13). During this infusion, a commercially available
ultrasound transducer (S3 probe, Sonos 5500, Philips Ultra-
sound, Bothell, WA) was directed to the right thigh of the
treated and control rats to disrupt the microbubbles within the
microcirculation. The probe was clamped in place. Ultrasound
was then applied in ultraharmonic mode (transmit 1.3 MHz/
receive 3.6 MHz) at a mechanical index of 1.4. Four bursts of
ultrasound were triggered to every fourth end-systole by elec-
trocardiogram using a delay of 45–70 msec after the peak of
the R wave. These settings have shown to be optimal for plas-
mid delivery by UTMD using this instrument (20). Microbubble
destruction was visually apparent in all rats. Blood samples
were drawn after an overnight 12 h fast at baseline and after
treatment. Blood glucose levels were measured; blood insulin
and free fatty acids (FFA) were measured with RIA kit (Linco
Research, Radioimmunoassay). SKM was harvested for histol-
ogy. Muscle tissue was collected from the left (treated) and
right (control) thighs (vastus lateralis) in all animals. All sam-
ples were placed in weigh boats and delivered to the process-
ing room by the surgical technicians immediately following
collection.
Immunohistochemistry
We fixed and processed tissues for immunohistochemistry
(IHC). The detection of UCP-1, PRDM16, BMP7, PGC-1alpha,
and perilipin from muscle tissue was assayed as follows: cryo-
stat sections 5 mm in thickness were fixed in 4% paraformalde-
hyde for 15 min at 4 8C and quenched for 5 min with 10 mM
glycine in PBS. Sections were then rinsed in PBS three times
and permeabilized with 0.5% Triton X-100 in PBS for 10 min.
Sections were blocked with 10% vol_vol goat serum at 37 8C
for 1 h and washed three times with PBS. The primary
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antibodies (rabbit polyclonal UCP-1 antibody, rabbit polyclonal
PRDM16 antibody, rabbit polyclonal BMP7 antibody, rabbit
polyclonal PGC-1alpha antibody, rabbit polyclonal perilipin
antibody, and mouse recombinant monoclonal Myf5 antibody
[OriGene Technologies]) were added and incubated at 4 8C
overnight. After washing with PBS three times for 5 min each
time, the secondary antibody was added and incubated for 1 h
at 37 8C. Sections were rinsed five times with PBS for 10 min
each time and then mounted. 40,6-diamidino-2-phenylindole
(1:5,000 dilution). The images were taken by Leica confocal
microscope TCS SP5.
Real Time RT-PCR analysis
Rat brain slices were obtained after euthanasia at the end of
the study to perform real time reverse transcription polymer-
ase chain reaction (RT-PCR; TaqMan assays, ThermoFisher
Technologies) and detect key hypothalamic genes influencing
energy balance (NPY, POMC, and SOCS3) and nutrient-sensing
(AMP-activated protein kinase [AMPK], mTOR, and TRPV1)
using an ABI PRISM 7900 HT sequence detection system (Life
Technologies Corporation, Carlsbad, CA).
Subcutaneous Abdominal Fat Thickness Measurement
with Ultrasound Image
An anatomical area in all four Zucker rats was carefully
defined on the left lateral wall of the abdomen. This area was
clipped and a reading was obtained with an A-mode device
using a focused transducer with a resonant frequency of 20
MHz (Sonos 5500, Philips Ultrasound, Bothell, WA). The thick-
ness of the subcutaneous abdominal fat layer was then calcu-
lated immediately after ultrasonic investigation.
Data Analysis
The primary endpoint of the POC study was to find out
whether gene therapy with BMP7/PRDM16/PPARGC1A in SKM
of obese ZDF (fa/fa) rats using UTMD technology would pro-
duce a BAT phenotype with UCP-1 overexpression. Then, we
decided to describe the trend from observations regarding
short-term changes in food consumption, fat mass evaluation
with ultrasound image (subcutaneous abdominal fat thickness
[SFT]), as well as key metabolic parameters (insulin, glucose,
and fatty acids) between the treated versus control obese
Zucker rats as a secondary objective. Even though the sample
size is small for formal statistical tests, the dispersion of mean
change in these parameters (Fig. 4) strongly suggests meta-
bolic alterations consistent with UCP-1 overexpression. Gene
expression for hypothalamic genes involved in energy homeo-
stasis and nutrient-sensing was calculated using the nonpara-
metric Mann-Whitney U (rank-sum) test. Graphics and statisti-
cal analysis were carried out using GraphPad Prism V 6.07.
Triple staining for muscle tissue in the left thigh at magnification of 3200. Robust in vivo UCP-1 signaling from BAT in SKM
after UTMD.FIG 1
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Results
To establish POC that UTMD is an effective method for in vivo
plasmid-based gene transfer in SKM, we administered a con-
struct into the SKM of four male ZDF (fa/fa) rats (56 days old),
a spontaneous genetic obesity model which exhibits hyperpha-
gia, hyperglycemia, hyperinsulinemia, and hyperlipidemia.
Intravenous microbubbles carrying plasmids with a cocktail of
BMP7/PRDM16/PPARGC1A genes were burst within the micro-
circulation of the left thigh by ultrasound (treated muscle) in
two rats, achieving local gene expression after targeting our
specific tissue. We were able to clearly demonstrate the ability
to disrupt microbubbles and release the plasmids with the
gene cocktail. We used the muscle of the right thigh as a con-
trol site in another two rats, administering UTMD with plas-
mids driving the DsRed reporter (marker) gene. We collected
muscle tissue from the left (treated) and right (control) thighs
in all four ZDF (fa/fa) rats. Our POC pilot lasted 30 days with a
20-day period of UTMD gene therapy.
We performed confocal microscopy with FITC-labeled anti-
UCP-1, DsRed-labeled anti-Myf5, and anti-perilipin for IHC.
Figure 1A,C shows triple staining for muscle tissue in the left
thigh at magnification of 3200. Anti-UCP-1 (red) and anti-
Myf5 (green) antibodies were used. Strong detection by IHC of
UCP-1 expression indicates that the gene combination of
PRDM16, PPARGC1A, and BMP7 reprogrammed adult SKM
into brown adipose cells after UTMD in vivo by day 10 (Fig.
1A) and 20 (Fig. 1C), respectively. Figure 1B,D show a strong
detection of Myf51 (green) and no UCP-1 signal detected in
the right thigh of the control rats (magnification at 3100). Fig-
ure 2A clearly shows precursors Myf51 in SKM cells transdif-
ferentiated into mature brown adipose cells in the muscle of
the left thigh in the treated rats. Clear signals for PRDM16
(red) (Fig. 2A) and PGC-1alpha (red) (Fig. 2C) are identified.
Figure 2B,D shows no detection of PRDM16 and PPARGC1A
activity in the muscle of the right thigh of control animals. Fig-
ure 3A,B shows presence in the muscle of the left thigh in
treated rats and absence in the muscle of the right thigh in
control rats of BMP7 activity. Figure 3C shows the presence of
perilipin antibody, a marker of adipose cells, detected at day
20 post UTMD gene delivery in the left thigh of treated rats.
There is an absence of activity for perilipin in the muscle of
the right thigh in control animals in Fig. 3D.
All rats were receiving 132 kcal/day of regular chow pel-
lets (Harlan rodent diet #2919, 3.3 kcal/g). Figure 4A shows
that their regular intake before UTMD gene therapy was 109
kcal/day. Daily food intake acutely decreased to 39.6 kcal/
day within the first 4 days after UTMD gene therapy in our
treated rats. These rats under PRDM16, PPARGC1A, and BMP7
gene therapy administration gradually increased their daily
food intake, recovering the intake levels previous to UTMD
Myf51 in SKM cells transdifferentiating into BAT with strong PRDM16 (A) and a fairly noticeable PGC-1alpha signaling (C).
PRDM16 acts to induce the expression of PGC-1alpha.FIG 2
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gene therapy by day 20. Figure 4B shows that all rats were
gaining equal weight previous to UTMD gene therapy as
expected (up to 50 g). However, the treated rats experienced
a sudden weight loss of 25 g in the first 4 days after UTMD
gene therapy. Their controls gained 30 g within the same
period of time. By day 20, treated rats reached a final weight
of 90 g despite having recovered the same amount of food
intake previous to UTMD gene therapy administration versus
their controls reaching 225 g (135 g difference).
Figure 4C shows that the weight loss from the treated rats
as a mean of fat thickness evaluated with ultrasound image
resulted in a greater percentage from fat mass (loss of 20.1 cm
by day 10 and a regain to 0.05 cm by day 20), compared with
controls (steady gain of 0.3 cm in 20 days). Figure 4D shows that
the change (D) in glucose circulating levels in the non-treated
control animals steadily rose up to 100 mg/dL by day 20. The (D)
blood glucose levels in the treated animals kept a low and steady
level of 12.5 mg/dL during the same period of days. Figure 4E
shows that the (D) insulin levels were lower by day 20 (–1,250
mIU/L) in the treated rats compared with the (D) insulin levels
(–650 mIU/L) found in the controls. Figure 4F shows the same
pattern for the (D) NEFA circulating levels: 20.15 mEq/L in the
controls versus 20.25 mEq/L in the treated rats at day 20.
Figure 6 shows the pattern of expression we obtained
from rat brain tissue at day 20. The differential expression of
key genes involved in appetite control and nutrient sensing
(NPY, POMC, TRPV1, and AMPK) were not significant. How-
ever, for two key genes, the levels of expression was higher in
the treated animals (SOCS3 levels of expression in treated 1.4
AU vs. controls 1.15 AU, and mTOR 1.3 AU levels in the
treated vs. 1.2 AU levels in the controls).
Discussion
This study was primarily designed to establish POC showing
that the administration of a gene combination of BMP7/
PRDM16/PPARGC1A to SKM in this rat model of genetic obe-
sity using UTMD gene therapy engineered a BAT phenotype
with UCP-1 over-expression.
Gene therapy-based approaches for obesity focus on the
transfer of gene coding or non-coding sequences to produce
critical proteins to re-establish metabolic homeostasis. The
potential application for gene therapy in treating obesity has
led to efforts centered on regulated expression using different
methods such as viral, non-viral, and synthetic delivery sys-
tems (21). UTMD, as a means of non-viral tissue-specific gene
delivery, attaches plasmid DNA vectors encoding a gene of
interest to shells of gas-filled lipid microbubble contrast
agents. Several key metabolic tissues have been targeted with
this UTMD gene delivery technique such as pancreas, adipose
tissue, kidney, heart, endothelium, and SKM (22,23).
Presence of BMP7 in SKM and perilipin activity at day 20 post UTMD gene therapy. BMP7 induces the expression of PRDM16
which functions to promote BAT gene expression and suppress the white fat program.FIG 3
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Our IHC results showed a reliable pattern of effective
UTMD-based gene delivery in enhancing SKM overexpression
of the UCP-1 gene (Fig. 1A and C). The data obtained seem to
suggest that our systemic gene delivery via UTMD, by increas-
ing local concentration of our transgene BMP7/PRDM16/
PPARGC1A cocktail (Figs. 1 and 2), allowed for efficient trans-
fection (via cavitation and tissue pore formation, through
ultrasound application and microbubble destruction), and was
capable of switching the precursor cell lineage and regulatory
myogenic factors for SKM development into the molecular
machinery necessary to establish a terminally differentiated
BAT and UCP-1 overexpression in vivo. Our group has
obtained similar results recently demonstrating that a single
UTMD treatment delivered to pancreatic islets of STZ-treated
rats with a cell cycle regulation gene cocktail cyclin D2/CDK4/
glucagon-like peptide 1 (CCND2/CDK4/GLP-1), resulted in
durable induction of b-cell regeneration without evidence of
toxicity (12). We have also generated important preliminary
data indicating that gene therapy by UTMD using the same
cell cycle regulation gene cocktail can achieve in vivo evidence
of islet regeneration and restoration of b-cell mass in baboons
(13).
Our POC results may support that from an evolutionary
perspective, the ability of BAT to produce facultative thermo-
genesis became so important that its contractile components
disappeared, although the very small, rapidly mobilizable lipid
droplets remained, ATP synthesis disappeared, large amounts
of mitochondria with a strong expression of the nuclear gene
UCP-1, the uncoupler of oxidative phosphorylation responsible
for non-shivering thermogenesis appeared, and a thermogenic
tissue of myogenic origin developed (24). Hence, some authors
currently consider BAT as a kind of specialized muscle (4).
We also observed interesting short-term changes in food
consumption, fat mass evaluation with ultrasound image
(SFT), as well as key metabolic parameters (insulin, glucose,
and fatty acids) between the treated versus control obese
Zucker rats. As shown in the results, the treated rats acutely
decreased their daily food intake during the 4 days following
gene therapy administration with the cell cycle regulation
gene cocktail, compared with the controls. They gradually
recover their food intake patterns to the levels shown previous
to UTMD gene therapy. All experimental animals experienced
the expected weight gain seen in a Zucker rat before UTMD
gene therapy. However, the weight pattern in the treated rats
showed a sudden weight loss within the same four days after
UTMD gene therapy, unlike their controls which kept gaining
weight during the same period of time. Interestingly, the
treated rats reached much less weight regain compared with
their controls by day 20 in spite of having recovered the same
amount of food intake previous to UTMD gene therapy admin-
istration (Fig. 4A,B). The loss of SFT with ultrasound image in
the treated Zucker rats was evident when compared with the
steady subcutaneous abdominal fat gain shown in the control
animals (Fig. 4C). The glucose, insulin, and NEFA showed low
(A) Changes from baseline in food intake (g), (B) body weight (g), and (C) fat thickness (cm) Zucker rats. Error bars represent
standard deviation (SD). The functional metabolic result of overexpressing UCP-1 in SKM observed in this figure nicely corre-
lated with hypophagia, and circulating levels of (D) glucose (mg/dL), (E) insulin, and (F) fatty acids (NEFA) in treated versus
control weight loss and metabolic improvement in the treated obese ZDF (fa/fa) rats for a short period of days.
FIG 4
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circulating levels in the UTMD gene therapy treated rats after
the administration of the UTMD gene cocktail by day 20 when
compared with the expected elevated circulating levels of these
three biomarkers measured in the control animals in the same
day (Fig. 4D–F).
These observations show that the functional metabolic
result of overexpressing UCP-1 in SKM nicely correlated with
hypophagia, weight loss, and metabolic improvement in the
treated obese ZDF (fa/fa) rats for a short period of days (Fig.
4A–F). They suggest that by administering the vector-carrying
microbubbles containing the cDNA of BMP7/PRDM16/
PPARGC1A into SKM an uncoupling of fatty acid and glucose
oxidation from ectopic UCP-1 overexpression may have been
enhanced. What we obtained was a localized level of expression
of UCP-1 only in SKM surrounding the site of the thigh exposed
to ultrasound implementation in the treated rats (Figs. 1–3).
The food intake of the treated rats markedly declined for a few
days correlating with weight loss and fat mass decrease in the
same rats when compared with their controls. Fat thickness
evaluated by ultrasound, insulin, and free fatty acid circulating
levels were lower in the treated rats overexpressing UCP-1 at
day 20. In particular, fasting blood glucose was remarkably
lower in these animals. These observed effects could reflect a
transient correction of metabolic abnormalities in this obese,
diabetic rat model. Therefore, we could assume that a limited
and confined amount of UCP-1 overexpression in SKM improved
systemic insulin sensitivity, serum lipid parameters, and
decreased fat mass accumulation, resulting in metabolic
improvement of the diabetic phenotype in congenital leptin
receptor-deficient ZDF (fa/fa) fatty rats.
These results are similar to the ones previously reported
in wild type (C57BL/6) obese diabetic mice models, where
A hypothetical mechanism by which gene therapy with BMP7/PRDM16/PPARGC1A in SKM of obese ZDF (fa/fa) rats using
UTMD technology would produce a BAT phenotype with UCP-1 overexpression leading to nutrient trafficking/sensing and an
energy gap, mediating hypophagia and metabolic improvement not regulated by leptin receptors.
FIG 5
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adenovirus containing the cDNA of UCP-1 was delivered into
the epididymal adipose tissue to induce fat depletion, resulting
in a marked decrease in food intake (10). Interestingly, in this
particular study, the researchers reported that the hypophagia
found in the wild-type obese mice overexpressing UCP-1 from
the epididymal fat pads could not be duplicated in the db/db
mice model with nonfunctioning and mutant leptin receptors,
concluding that such hypophagia was leptin-signaling depen-
dent. They also found improvement in blood glucose, insulin,
triglyceride and fatty-acid levels, glucose tolerance, and insulin
sensitivity in both the wild type and the db/db congenital
model, concluding that the metabolic improvements observed
were independent of the leptin signaling pathway (10).
In our study, it is worth noting that the obese ZDF (fa/fa)
fatty rats carrying an equivalent missense mutation in the lep-
tin receptor gene as in the db/db mice, also overexpressed
UCP-1, but from SKM. They became transiently hypophagic,
lost weight and fat mass, and their blood glucose, insulin and
FFA markedly improved. We speculate that perhaps the rea-
son for the anorectic response and metabolic improvement
observed in our ZDF (fa/fa) rats with nonfunctional and
mutant leptin receptors, as it was observed in the wild-type
mice but not in the db/db model (10), may be related to the
fact that the site of UCP-1 overexpression in our congenital
obese rats was SKM, not WAT, also occurring without the
presence of a functional leptin signaling pathway.
Of note, leptin-resistant states due to loss-of-function
mutations of the leptin receptor cause severe lipotoxicity. The
ZDF fa/fa rats are the most extensively studied model of con-
genital leptin resistance, caused by a loss-of-function in the
leptin receptor (25). The lack of leptin action on their thermo-
genic centers in the hypothalamus leads rapidly to obesity.
Appetite, adipose tissue mass and plasma FFA increase
steadily in these animals, leading to triglyceride accumulation
in SKM, liver, pancreas and kidneys (26). We were able to
ameliorate to some extent and for a short period of time these
metabolic derangements with UCP-1 overexpression through
UTMD-based gene therapy in SKM in our Zucker fa/fa congen-
ital rat model. Therefore, an interesting challenge arising from
these POC preliminary results is to determine the molecular
mechanisms underlying the hypophagia and the positive meta-
bolic effects triggered through a single UCP-1 overexpression
in these ZDF (fa/fa) rats.
It is important, however, to bear in mind that this is a lim-
ited POC pilot study which needs to be interpreted carefully.
All data gathered from this protocol will be used to design
larger confirmatory studies and dictate the future direction of
our research. This will include replicating this protocol in wild
type rats and/or non-human primates using a calorie-dense
palatable diet to induce them to become obese. We will collect
EE data, body temperature, and measure BAT thermogenesis
using infrared imaging and RT-PCR techniques to detect UCP-1
activity in vivo (27). Another limitation of this POC pilot study
was the number of treated vs. control ZDF (fa/fa) rats (N54).
One more limitation was the lack of measurements of daily
EE. Indeed, if the reason to induce BAT thermogenesis
through gene therapy is to achieve weight loss, hypophagia,
and metabolic improvement, a fundamental question would be
how much EE would have to occur with our UTMD gene ther-
apy approach to reach clinically successful outcomes. This
leads to another equally important question of how much
mass of BAT should be induced in excess of what mammals
normally possess to achieve appropriate metabolic improve-
ment without producing deleterious side effects. Total volume
of BAT in most humans has been reported in the range of
100–200 grams (28). The answers to these questions remain to
be elucidated.
Nevertheless, our study documents the feasibility of UTMD
gene-base therapy administration in SKM, the overexpression of
UCP-1 by IHC after delivery of the transgene BMP7/PRDM16/
PPARGC1A cocktail, transient hypophagia, weight loss, SQ fat
mass depletion measured through ultrasound, and improve-
ment of insulin sensitivity and key metabolic parameters such
as circulating FFA and glucose. Taken together, these findings
may suggest that the metabolic improvement and weight loss
may not have been mediated by leptin receptors from the hypo-
thalamic leptin signaling pathway, since it occurred in the ZDF
(fa/fa) rat. Therefore, we speculate that an anoretic action com-
bined with a metabolic effect could have been triggered by a
single administration of UTMD-based transgenes and localized
UCP-1 overexpression in SKM, achieved independently of the
leptin signaling pathway (Fig. 5).
While the biological mechanisms underlying the short-term
anorexigenic and metabolic effects obtained in this study
remain to be unraveled, the results seem to indicate that the
SKM, if genetically engineered, possesses the molecular capabil-
ity to fully regulate calorie intake, substrate trafficking, and
central and peripheral metabolism. Therefore, perhaps the
Pattern of expression obtained through RT-PCR of
key hypothalamic genes involved in energy homeo-
stasis (NPY, POMC, and SOCS3), and nutrient-
sensing (AMPK, mTOR, and TRPV1) at day 20 post
UTMD gene therapy. Red bars: treated Zucker rats.
Blue bars: control Zucker rats.
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observed metabolic and anorexigenic effects could be mediated
by cellular pathways related to nutrient-sensing homeostatic
mechanisms (29). Indeed, recent findings seem to indicate that
AMPK and mammalian target of rapamycin (mTOR), two inter-
connected major junctions playing key roles in metabolism,
have a major impact in the control of brown adipogenesis pro-
cess, nutrient-sensing and regulation of energy balance (29).
We tried to explore this possibility by analyzing key hypo-
thalamic genes involved in energy homeostasis (NPY, POMC,
and SOCS3) and nutrient-sensing (AMPK, mTOR, and TRPV1)
through RT-PCR in our treated and control animals (30–32).
Figure 6 shows the pattern of expression we obtained.
Although we did not find significance differences, we did notice
a slight increase in SOCS3 and mTOR expression in the treated
animals which appears to correlate with the recovery of food
ingestion and the more pronounced weight loss, perhaps
related to an overwhelming substrate trafficking secondary to
the transient UCP-1 over activity in SKM from days 10 to 20
after UTMD gene therapy. Indeed, recent scientific evidence
suggests that circulating substrates (macronutrients such as
fatty acids and amino acids) have specific actions to activate
receptors and signaling pathways, in addition to providing fuel
and essential nutrients. They can exert their effects on target
tissues such as the hypothalamus by acting on cell-surface
receptors through intracellular signaling cascades or via
nuclear receptors to regulate gene transcription (33). Based on
this evidence and our preliminary results, we could speculate
that a measurement of these hypothalamic genes at an earlier
time of the study would have given perhaps a more rational
picture on behalf of our leptin-independent nutrient-sensing
homeostatic working hypothesis explaining the hypophagia,
weight loss and fat mass depletion.
A final intriguing observation was the curve of food intake
and weight loss in the treated rats (Fig. 4A,B). These animals
gradually recovered their food intake patterns by day 20,
when compared with the patterns they showed before UTMD
gene therapy administration and to the food intake of their
controls. The weight loss in the treated rats never recovered
the levels observed in the controls despite food intake recov-
ery. This finding may be associated with the new “energy gap”
concept (34). As an example, the Swedish Obesity Subjects
(SOS) trial (35) showed that the efficacy of bariatric surgery to
long-term weight loss is about 20 kg on average over 10–15
years. An analysis of the fall in EE for long-term weight loss
achieved by bariatric surgery in the SOS trial seems to have
been effective in stimulating daily EE by approximately 600
kcal daily (considered the energy gap for long-term mainte-
nance, and subdivided into components that represent passive
[obligatory] and active [adaptive thermogenesis] components),
assuming no change in energy intake (36). Given that an
increase in 24-h EE documented from any thermogenic com-
pound at a safe dose is less than 150 kcal/day, a valid question
would be whether the human body is able to reach a thermo-
genic capacity from BAT to achieve similar long-term weight
loss as the one obtained in the SOS trial (37). In our POC study,
the food intake and weight curves from days 0 to 20 after the
administration of the gene cocktail of BMP7/PRDM16/
PPARGC1A to treated Zucker rats (Fig. 4A,B) may reflect the
energy gap hypothesis, where EE through BAT over activity
secondary to UTMD gene therapy in muscle could have
avoided weight regain in spite of the gradual recovery of their
food intake patterns.
In conclusion, the preliminary results obtained in this POC
pilot project may open a window to future innovative thera-
peutic strategies through gene therapy to treat and prevent
cardiometabolic risk factors related to nutrition.
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